WO2021259315A1 - 化合物的盐以及包含盐的药物组合物 - Google Patents
化合物的盐以及包含盐的药物组合物 Download PDFInfo
- Publication number
- WO2021259315A1 WO2021259315A1 PCT/CN2021/101778 CN2021101778W WO2021259315A1 WO 2021259315 A1 WO2021259315 A1 WO 2021259315A1 CN 2021101778 W CN2021101778 W CN 2021101778W WO 2021259315 A1 WO2021259315 A1 WO 2021259315A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- amorphous
- equivalent
- salt
- sample number
- Prior art date
Links
- HSHLPLLTDGIMDL-UHFFFAOYSA-N CN(C)CCN(C)c(c(NC(C=C)=O)c1)cc(OC)c1Nc1ncnc(-c2c[n](C)c3ccccc23)n1 Chemical compound CN(C)CCN(C)c(c(NC(C=C)=O)c1)cc(OC)c1Nc1ncnc(-c2c[n](C)c3ccccc23)n1 HSHLPLLTDGIMDL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (8)
- 根据权利要求1所述的盐,其中所述酸选自:盐酸、甲磺酸和马来酸。
- 根据权利要求1或2所述的盐,其中式(I)化合物与酸的当量比为1:1或1:2。
- 根据权利要求3所述的盐,其中所述酸为甲磺酸。
- 根据权利要求4所述的盐,其中式(I)化合物与酸的当量比为1:1。
- 一种药物组合物,其包含根据权利要求1-5中任一项所述的盐和药学上可接受的载体。
- 一种治疗EGFR外显子20插入突变的非小细胞肺癌(NSCLC)的方法,包括将根据权利要求1-5中任一项所述的盐或根据权利要求6的药物组合物给药于患者。
- 根据权利要求1-5中任一项所述的盐在制备用于治疗EGFR外显子20插入突变的非小细胞肺癌(NSCLC)的药物中的用途。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021294796A AU2021294796A1 (en) | 2020-06-23 | 2021-06-23 | Salt of compound and pharmaceutical composition containing salt |
CN202180029937.XA CN115734968A (zh) | 2020-06-23 | 2021-06-23 | 化合物的盐以及包含盐的药物组合物 |
US18/002,578 US20230234941A1 (en) | 2020-06-23 | 2021-06-23 | Salts of Compound and Pharmaceutical Compositions Containing the Same |
KR1020237000352A KR20230026383A (ko) | 2020-06-23 | 2021-06-23 | 화합물의 염 및 염을 포함하는 약학적 조성물 |
JP2022580228A JP2023531077A (ja) | 2020-06-23 | 2021-06-23 | 化合物の塩、及び塩を含む医薬組成物 |
EP21828291.1A EP4169914A1 (en) | 2020-06-23 | 2021-06-23 | Salt of compound and pharmaceutical composition containing salt |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010579560.2 | 2020-06-23 | ||
CN202010579560 | 2020-06-23 | ||
CN202110563762.2 | 2021-05-22 | ||
CN202110563762 | 2021-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021259315A1 true WO2021259315A1 (zh) | 2021-12-30 |
Family
ID=79282005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/101778 WO2021259315A1 (zh) | 2020-06-23 | 2021-06-23 | 化合物的盐以及包含盐的药物组合物 |
PCT/CN2021/101779 WO2021259316A1 (zh) | 2020-06-23 | 2021-06-23 | 化合物的结晶形式 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/101779 WO2021259316A1 (zh) | 2020-06-23 | 2021-06-23 | 化合物的结晶形式 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230234941A1 (zh) |
EP (2) | EP4169915A1 (zh) |
JP (2) | JP2023531078A (zh) |
KR (2) | KR20230026384A (zh) |
CN (2) | CN116075504A (zh) |
AU (2) | AU2021294553A1 (zh) |
WO (2) | WO2021259315A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015195228A1 (en) * | 2014-06-19 | 2015-12-23 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
CN105461695A (zh) | 2014-09-29 | 2016-04-06 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
CN106928200A (zh) * | 2015-12-30 | 2017-07-07 | 湖南福沃药业有限公司 | 用于治疗癌症的三嗪衍生物 |
WO2017205459A1 (en) * | 2016-05-26 | 2017-11-30 | Kalyra Pharmaceuticals, Inc. | Egfr inhibitor compounds |
CN108864079A (zh) * | 2017-05-15 | 2018-11-23 | 深圳福沃药业有限公司 | 一种三嗪化合物及其药学上可接受的盐 |
WO2020200158A1 (zh) * | 2019-03-29 | 2020-10-08 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
-
2021
- 2021-06-23 AU AU2021294553A patent/AU2021294553A1/en active Pending
- 2021-06-23 WO PCT/CN2021/101778 patent/WO2021259315A1/zh unknown
- 2021-06-23 CN CN202180044161.9A patent/CN116075504A/zh active Pending
- 2021-06-23 KR KR1020237000357A patent/KR20230026384A/ko unknown
- 2021-06-23 AU AU2021294796A patent/AU2021294796A1/en active Pending
- 2021-06-23 WO PCT/CN2021/101779 patent/WO2021259316A1/zh unknown
- 2021-06-23 US US18/002,578 patent/US20230234941A1/en active Pending
- 2021-06-23 JP JP2022580229A patent/JP2023531078A/ja active Pending
- 2021-06-23 CN CN202180029937.XA patent/CN115734968A/zh active Pending
- 2021-06-23 JP JP2022580228A patent/JP2023531077A/ja active Pending
- 2021-06-23 KR KR1020237000352A patent/KR20230026383A/ko unknown
- 2021-06-23 EP EP21829316.5A patent/EP4169915A1/en active Pending
- 2021-06-23 EP EP21828291.1A patent/EP4169914A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015195228A1 (en) * | 2014-06-19 | 2015-12-23 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
CN105461695A (zh) | 2014-09-29 | 2016-04-06 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
CN106928200A (zh) * | 2015-12-30 | 2017-07-07 | 湖南福沃药业有限公司 | 用于治疗癌症的三嗪衍生物 |
WO2017205459A1 (en) * | 2016-05-26 | 2017-11-30 | Kalyra Pharmaceuticals, Inc. | Egfr inhibitor compounds |
CN108864079A (zh) * | 2017-05-15 | 2018-11-23 | 深圳福沃药业有限公司 | 一种三嗪化合物及其药学上可接受的盐 |
WO2020200158A1 (zh) * | 2019-03-29 | 2020-10-08 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
Also Published As
Publication number | Publication date |
---|---|
KR20230026384A (ko) | 2023-02-24 |
WO2021259316A1 (zh) | 2021-12-30 |
JP2023531078A (ja) | 2023-07-20 |
EP4169914A1 (en) | 2023-04-26 |
AU2021294553A1 (en) | 2022-09-22 |
EP4169915A1 (en) | 2023-04-26 |
US20230234941A1 (en) | 2023-07-27 |
JP2023531077A (ja) | 2023-07-20 |
KR20230026383A (ko) | 2023-02-24 |
CN116075504A (zh) | 2023-05-05 |
AU2021294796A1 (en) | 2022-09-22 |
CN115734968A (zh) | 2023-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10596158B2 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
US8754104B2 (en) | Crystalline salts of quinoline compounds and methods for preparing them | |
CZ20022875A3 (cs) | Nová krystalická forma kyseliny N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo2.3-d]-pyrimidin-5-yl)ethyl]benzoyl]-L-glutamové a způsob její přípravy | |
KR20070053205A (ko) | 의약 조성물 | |
CZ283181B6 (cs) | Farmaceutická činidla | |
EP2991999A1 (en) | Co-crystals of dapagliflozin | |
EP3183253B1 (en) | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid | |
EP2916915A1 (en) | Amine salts of laquinimod | |
KR20030069796A (ko) | 졸피뎀 헤미타르트레이트 | |
BR112019022002A2 (pt) | Novo composto sólido cristalino de cloridrato de 3-fenil-4-propil-1-(piridin-2-il)-1-h-pirazol-5-ol | |
WO2021259315A1 (zh) | 化合物的盐以及包含盐的药物组合物 | |
CN112654607B (zh) | 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型 | |
CN111171031B (zh) | 一种含parp抑制剂倍半水合物产物的制备方法 | |
JP2001503374A (ja) | 凍結乾燥チオキサンテノン抗腫瘍剤 | |
US10344041B2 (en) | Polymorphic forms and co-crystals of a c-Met inhibitor | |
CA3067271A1 (en) | Crystalline forms of ponatinib hydrochloride | |
WO2021208055A1 (zh) | 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用 | |
WO2023061437A1 (zh) | 抗肿瘤药物的盐及其晶型 | |
US20230265043A1 (en) | Crystalline form of phentermine hydrochloride and process for obtaining same | |
EP4137133A1 (en) | Crystalline form of avacopan | |
WO2022263263A1 (en) | Crystalline form of avacopan | |
WO2018054359A1 (zh) | 一种喹唑啉衍生物的盐、其制备方法及应用 | |
TW202402757A (zh) | 7H-吡咯[2,3-d〕嘧啶-4-胺衍生物之結晶 | |
NO783005L (no) | Fremgangsmaate for fremstilling av et arylpyridazinylhydrazinsalt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21828291 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021294796 Country of ref document: AU Date of ref document: 20210623 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022580228 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237000352 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021828291 Country of ref document: EP Effective date: 20230123 |